RU2228204C2 - Method for treating the cases of trophic ulcers on the background of diabetic foot syndrome - Google Patents
Method for treating the cases of trophic ulcers on the background of diabetic foot syndrome Download PDFInfo
- Publication number
- RU2228204C2 RU2228204C2 RU2002109851/14A RU2002109851A RU2228204C2 RU 2228204 C2 RU2228204 C2 RU 2228204C2 RU 2002109851/14 A RU2002109851/14 A RU 2002109851/14A RU 2002109851 A RU2002109851 A RU 2002109851A RU 2228204 C2 RU2228204 C2 RU 2228204C2
- Authority
- RU
- Russia
- Prior art keywords
- autolymphocytes
- background
- diabetic foot
- treating
- foot syndrome
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 230000001228 trophic effect Effects 0.000 title claims description 8
- 208000025865 Ulcer Diseases 0.000 title claims description 7
- 231100000397 ulcer Toxicity 0.000 title claims description 7
- 208000008960 Diabetic foot Diseases 0.000 title claims description 5
- 208000011580 syndromic disease Diseases 0.000 title claims description 5
- 210000000601 blood cell Anatomy 0.000 claims abstract description 4
- 210000001105 femoral artery Anatomy 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 3
- DRFILBXQKYDTFW-JIWRMXRASA-L disodium;2-[[(2r)-2-[[(4s)-4-amino-4-carboxybutanoyl]amino]-3-[[(2r)-2-[[(4s)-4-amino-4-carboxybutanoyl]amino]-3-(carboxylatomethylamino)-3-oxopropyl]disulfanyl]propanoyl]amino]acetate Chemical compound [Na+].[Na+].OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC([O-])=O)CSSC[C@@H](C(=O)NCC([O-])=O)NC(=O)CC[C@H](N)C(O)=O DRFILBXQKYDTFW-JIWRMXRASA-L 0.000 claims description 5
- 108010068227 glutoxim Proteins 0.000 claims description 5
- 239000002955 immunomodulating agent Substances 0.000 claims description 5
- 230000002584 immunomodulator Effects 0.000 claims description 5
- 229940121354 immunomodulator Drugs 0.000 claims description 5
- 238000001361 intraarterial administration Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 abstract description 2
- 230000032630 lymph circulation Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 210000003414 extremity Anatomy 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 5
- 210000002751 lymph Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- JBFLYOLJRKJYNV-MASIZSFYSA-N (1z)-1-[(3,4-diethoxyphenyl)methylidene]-6,7-diethoxy-3,4-dihydro-2h-isoquinoline;hydron;chloride Chemical compound Cl.C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 JBFLYOLJRKJYNV-MASIZSFYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Изобретение относится к медицине, а именно к хирургии и эфферентной терапии, может быть использовано в качестве лечения трофических язв на фоне синдрома диабетической стопы.The invention relates to medicine, namely to surgery and efferent therapy, can be used as a treatment for trophic ulcers against the background of diabetic foot syndrome.
Существуют методы лечения трофических язв на фоне синдрома диабетической стопы путем внутриартериального введения спазмолитиков, препаратов простагландина Е1 (вазопростан (Vidal 2001)).There are methods for treating trophic ulcers in the presence of diabetic foot syndrome by intraarterial administration of antispasmodics, prostaglandin E1 preparations (vasoprostan (Vidal 2001)).
Технический результат предлагаемого способа - повышение эффективности лечения путем внутриартериального введения аутолимфоцитов, обработанных иммуномодулятором глутоксим, что приводит к активизации иммунологических, метаболических и репаративных процессов в пораженной конечности.The technical result of the proposed method is to increase the effectiveness of treatment by intraarterial administration of autolymphocytes treated with the immunomodulator glutoxim, which leads to the activation of immunological, metabolic and reparative processes in the affected limb.
Поставленная цель достигается путем использования лимфоцитафереза на сепараторе клеток крови AS-TEC 204 фирмы “Fresenius”. Полученные аутолимфоциты в концентрации 400-1000 клеток/мл экспонируются в течение 45 мин с 20 мг глутоксима при температуре 24-26°С, после чего аутолимфоциты возвращаются пациенту путем инфузии в бедренную артерию пораженной конечности. С целью профилактики сосудистого спазма перед введением аутолимфоцитов внутриартериально вводится спазмолитик но-шпа - 2 мл в разведении физиологическим раствором до 10 мл. Данная процедура повторяется дважды с интервалом 48-72 ч.The goal is achieved by using lymphocytapheresis on a blood cell separator AS-TEC 204 from Fresenius. The obtained autolymphocytes at a concentration of 400-1000 cells / ml are exposed for 45 minutes with 20 mg of glutoxim at a temperature of 24-26 ° C, after which the autolymphocytes are returned to the patient by infusion into the femoral artery of the affected limb. In order to prevent vascular spasm, before administration of autolymphocytes, an antispasmodic no-spa is introduced intraarterially - 2 ml diluted with saline to 10 ml. This procedure is repeated twice with an interval of 48-72 hours.
Больные группы контроля и сравнения (с назначением курса лимфоцитаферезов) получали местное лечение трофических язв: мази на водорастворимой основе (“левомеколь”, “левосин”) в фазе 2 и 3 раневого процесса и традиционную терапию (актовегин, трентал, никотиновая кислота, витамины группы В, антибиотики широкого спектра действия - цефтриабол+гентамицин, инсулинотерапия).Patient control and comparison groups (with the appointment of a course of lymphocytapheresis) received topical treatment of trophic ulcers: ointments on a water-soluble basis (“levomekol”, “levosin”) in phases 2 and 3 of the wound healing process and traditional therapy (actovegin, trental, nicotinic acid, vitamins of the group B, broad-spectrum antibiotics - ceftriabol + gentamicin, insulin therapy).
Преимущества заявляемого решения:The advantages of the proposed solutions:
- выделение точного количества аутолимфоцитов, клеток, занимающих одно из центральных мест в иммунной системе организма, выполняющих защитную, иммунорегуляторную и в определенной степени трофическую функцию;- allocation of the exact number of autolymphocytes, cells, occupying one of the central places in the body’s immune system, performing a protective, immunoregulatory and, to a certain extent, trophic function;
- прицельное воздействие иммуномодулятором на аутолимфоциты в экстракорпоральных условиях;- targeted action of an immunomodulator on autolymphocytes in extracorporeal conditions;
- подведение аутолимфоцитов, обработанных иммуномодулятором, через артериальную систему пораженной ноги непосредственно в зону трофического дефекта.- summing up autolymphocytes treated with an immunomodulator through the arterial system of the affected leg directly into the area of the trophic defect.
Оценка результатов лечения проводилась по следующему алгоритму:Assessment of treatment results was carried out according to the following algorithm:
- сроки появления грануляционной ткани в ране;- the timing of the appearance of granulation tissue in the wound;
- сроки эпителизации ран;- timing of wound epithelization;
- сроки применения кожной пластики;- the timing of the use of skin grafting;
- койко-день.- bed day.
Были проведены следующие исследования:The following studies were carried out:
- оценка количества лейкоцитов в периферической крови, лейкоцитарная формула;- assessment of the number of leukocytes in peripheral blood, leukocyte formula;
- цитологическое исследование мазков-отпечатков ран;- cytological examination of smears, prints of wounds;
- реолимфовазография сосудов пораженной и контрлатеральной конечностей.- reolymphovasography of blood vessels of the affected and contralateral limbs.
При использовании предлагаемого способа лечения грануляционная ткань в ране появлялась на 6.2 суток, против 10-12 суток в группе контроля. Появление краевой и очаговой эпителизации ран происходило на 7.3 суток при использовании лимфоцитафереза и внутриартериального введения аутолимфоитов с глутоксимом и на 13 сутки в группе контроля. Данными реолимфовазографии после лечения было зарегистрировано достоверное увеличение объема и скорости оттока лимфы и венозной крови по периферическим сосудам при исходном снижении данных показателей в сравнении со здоровой конечностью. В группе контроля показатели скорости и объема оттока лимфы и венозной крови до и после лечения не претерпевали достоверных изменений. Регенераторный тип цитограммы наблюдался при использовании традиционного метода лечения на 10 сутки, а при использовании предлагаемого способа на 5-6 сутки. Данные других лабораторных показателей коррелировали с клинической картиной болезни. Средний койко-день при использовании предлагаемого способа лечения составил 28 суток, а при использовании традиционного метода лечения - 37 суток.When using the proposed method of treatment, granulation tissue in the wound appeared for 6.2 days, against 10-12 days in the control group. The appearance of marginal and focal epithelialization of wounds occurred on 7.3 days when using lymphocytapheresis and intraarterial administration of autolymphoites with glutoxim and on day 13 in the control group. After treatment with reolymphasovography, a significant increase in the volume and speed of outflow of lymph and venous blood through peripheral vessels was recorded with an initial decrease in these indicators compared with a healthy limb. In the control group, the rate and volume of outflow of lymph and venous blood before and after treatment did not undergo significant changes. The regenerative type of cytogram was observed using the traditional method of treatment on the 10th day, and when using the proposed method on the 5-6th day. Data from other laboratory parameters correlated with the clinical picture of the disease. The average bed-day when using the proposed method of treatment was 28 days, and when using the traditional method of treatment - 37 days.
Клинический пример. Пациент Т-в, 67 лет. Диагноз п/о: Синдром диабетической стопы. Трофическая язва правой стопы. Сопутствующий диагноз: Сахарный диабет, 2 тип, средней степени тяжести, инсулинпотребный, субкомпенсация. Диабетическая нейропатия нижних конечностей, нефропатия. Страдает сахарным диабетом в течение 12 лет. 08.02.2001 в Усть-Каменогорске выполнена ампутация I пальца правой стопы. В послеоперационном периоде сформировалась длительно незаживающая рана. При поступлении правая стопа отечна +2 см. В I межпальцевом промежутке имеется рана размерами до 5×3 см. Отделяемое серозно-гнойное. Рана выполнена фибрином и некрозами. В дне раны кость, не прикрытая мягкими тканями. Пульсации на тыльной артерии правой стопы нет. По данным реолимфовазографии на пораженной конечности снижение объема и скорости оттока лимфы и венозной крови по периферическим сосудам по сравнению с контрлатеральной конечностью. По данным мазков-отпечатков ран имелся воспалительный тип цитограммы. Проведена некрэктомия области правой стопы. Консервативное лечение - повязки с левосином, стандартная метаболическая терапия, антибактериальная терапия. Проведено 2 сеанса лимфоцитафереза на сепараторе клеток крови, получены аутолимфоциты, которые после активации иммуномодулятором глутоксим, введены в бедренную артерию правой нижней конечности. Получены следующие результаты: грануляционная ткань появилась на 6 сутки после начала курса лимфоцитафереза, краевая и очаговая эпителизация на 7 сутки, полная эпителизация на 20 сутки. Данными контрольной лимфореовазографии подтверждено увеличение объема и скорости оттока лимфы и венозной крови по периферическими сосудам.Clinical example. Patient T., 67 years old. Diagnosis n / a: Diabetic foot syndrome. Trophic ulcer of the right foot. Concomitant diagnosis: Diabetes mellitus, type 2, moderate, insulin-consuming, subcompensation. Diabetic neuropathy of the lower extremities, nephropathy. Suffers from diabetes for 12 years. 02/08/2001 in Ust-Kamenogorsk amputation of the first toe of the right foot was performed. In the postoperative period, a long non-healing wound was formed. Upon admission, the right foot is swollen +2 cm. In the I interdigital space, there is a wound up to 5 × 3 cm in size. Separated serous-purulent. The wound is made by fibrin and necrosis. At the bottom of the wound is a bone that is not covered by soft tissue. There is no pulsation on the dorsal artery of the right foot. According to reolymphazovography on the affected limb, a decrease in the volume and speed of outflow of lymph and venous blood through the peripheral vessels compared with the contralateral limb. According to smear imprints of wounds, there was an inflammatory type of cytogram. A necrectomy of the region of the right foot was performed. Conservative treatment - dressings with levosin, standard metabolic therapy, antibiotic therapy. 2 sessions of lymphocytapheresis were performed on a blood cell separator, autolymphocytes were obtained, which, after activation by the immunomodulator Glutoxim, were introduced into the femoral artery of the right lower limb. The following results were obtained: granulation tissue appeared on the 6th day after the start of the course of lymphocytapheresis, marginal and focal epithelization on the 7th day, complete epithelization on the 20th day. Data from control lymphoreovasography confirmed an increase in the volume and speed of the outflow of lymph and venous blood through peripheral vessels.
Предложенный способ позволяет эффективно влиять на гипореактивность тканей пораженной конечности, обеспечивает более быстрое закрытие язвенного дефекта, улучшает кровоток и лимфоток в пораженной конечности, что повышает детоксикационные способности данного региона.The proposed method allows you to effectively influence the hyporeactivity of tissues of the affected limb, provides faster closure of the ulcer, improves blood flow and lymph flow in the affected limb, which increases the detoxification abilities of this region.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2002109851/14A RU2228204C2 (en) | 2002-04-15 | 2002-04-15 | Method for treating the cases of trophic ulcers on the background of diabetic foot syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2002109851/14A RU2228204C2 (en) | 2002-04-15 | 2002-04-15 | Method for treating the cases of trophic ulcers on the background of diabetic foot syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2002109851A RU2002109851A (en) | 2003-12-10 |
| RU2228204C2 true RU2228204C2 (en) | 2004-05-10 |
Family
ID=32678465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002109851/14A RU2228204C2 (en) | 2002-04-15 | 2002-04-15 | Method for treating the cases of trophic ulcers on the background of diabetic foot syndrome |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2228204C2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2294767C1 (en) * | 2005-07-11 | 2007-03-10 | ГУ Научно-исследовательский институт клинической и экспериментальной лимфологии СО РАМН | Method for lymphostimulation in case of affected disorders of hemolymphocirculation of inferior limbs in patients with diabetic foot syndrome |
| RU2332990C1 (en) * | 2007-03-27 | 2008-09-10 | ГУ Научно-исследовательский институт клинической и экспериментальной лимфологии СО РАМН | Method for treatment of trophic ulcers in patients with diabetes |
| MD696Z (en) * | 2013-03-26 | 2014-12-31 | Адриан КУШНИР | Method for treatment of diabetic foot complications |
| MD1179Z (en) * | 2017-03-29 | 2018-03-31 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Method for treating trophic ulcers |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LV12448B (en) * | 1998-09-23 | 2000-07-20 | Venta �IDLOVSKA | LOWER EXTREMITIVE LEATHER TROPICAL SHEET DEVELOPMENT DIAGNOSTIC METHODS |
| RU2159640C1 (en) * | 1999-11-30 | 2000-11-27 | Шевцов Юрий Николаевич | Method for treating patients suffering from chronic critical lower extremity ischemia in preoperation period |
| RU2178310C1 (en) * | 2000-12-18 | 2002-01-20 | Древаль Александр Васильевич | Method to treat ulcerous defects at diabetic foot syndrome |
-
2002
- 2002-04-15 RU RU2002109851/14A patent/RU2228204C2/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LV12448B (en) * | 1998-09-23 | 2000-07-20 | Venta �IDLOVSKA | LOWER EXTREMITIVE LEATHER TROPICAL SHEET DEVELOPMENT DIAGNOSTIC METHODS |
| RU2159640C1 (en) * | 1999-11-30 | 2000-11-27 | Шевцов Юрий Николаевич | Method for treating patients suffering from chronic critical lower extremity ischemia in preoperation period |
| RU2178310C1 (en) * | 2000-12-18 | 2002-01-20 | Древаль Александр Васильевич | Method to treat ulcerous defects at diabetic foot syndrome |
Non-Patent Citations (1)
| Title |
|---|
| KOZHEMIAKIN L.A. et al. Molecular genetic aspects of the antineoplas effect of gluthoxim. Vopr. Oncol. 2001; 47(3): 338-42. * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2294767C1 (en) * | 2005-07-11 | 2007-03-10 | ГУ Научно-исследовательский институт клинической и экспериментальной лимфологии СО РАМН | Method for lymphostimulation in case of affected disorders of hemolymphocirculation of inferior limbs in patients with diabetic foot syndrome |
| RU2332990C1 (en) * | 2007-03-27 | 2008-09-10 | ГУ Научно-исследовательский институт клинической и экспериментальной лимфологии СО РАМН | Method for treatment of trophic ulcers in patients with diabetes |
| MD696Z (en) * | 2013-03-26 | 2014-12-31 | Адриан КУШНИР | Method for treatment of diabetic foot complications |
| MD1179Z (en) * | 2017-03-29 | 2018-03-31 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Method for treating trophic ulcers |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO170194B (en) | PROCEDURE FOR THE PREPARATION OF PHYSIOLOGICALLY ACTIVE HEALTH SUBSTANCES | |
| Lowe et al. | Double-blind controlled clinical trial of ancrod for ischemic rest pain of the leg | |
| RU2228204C2 (en) | Method for treating the cases of trophic ulcers on the background of diabetic foot syndrome | |
| RU2616239C2 (en) | Method for erosive and ulcerative skin lesions treatment | |
| RU2214256C2 (en) | Agent for stimulation of cells proliferation, composite for stimulation of cells proliferation and method for treatment of wounds, burns and ulcers of different etiology | |
| RU2179853C1 (en) | Method for preventing and treating the cases of angio- and neuropathies concomitant to diabetes mellitus | |
| Cope | The chemical aspects of burn treatment | |
| RU2484837C2 (en) | Method of treating trophic ulcers | |
| RU2092107C1 (en) | Method for treatment hepatic insufficiency in patients affected with ascites | |
| RU2482894C1 (en) | Method of combined treatment of children with severe thermal injury | |
| SU1801487A1 (en) | Method for trophic ulcers treatment | |
| RU2328288C1 (en) | Method of inferior limb trophic ulcers treatment associated with postthrombotic disease | |
| RU2842825C1 (en) | Method of treating diffuse purulent peritonitis | |
| RU2753136C1 (en) | Method for autodermoplasty with split-thickness graft for restoration of skin after burns | |
| RU2188012C2 (en) | Method for treating the patients with primary biliary cirrhosis at applying the cryoheparinoprecipitation | |
| RU2345752C1 (en) | Method of secondary osteoporosis treatment | |
| SU1287869A1 (en) | Method of treatment of patients ill with trophic ulcers of the shin | |
| RU2508097C1 (en) | Method for multimodality therapy for diabetic foot | |
| RU2357736C1 (en) | Method of aseptic whirlbone necrosis and perthers disease treatment | |
| RU2239467C2 (en) | Combined medicamentous and laser method for treating purulent diseases of fingers and hand | |
| RU2293554C1 (en) | Method for treating inflammatory diseases of broncho-pulmonary system of bacterial etiology | |
| RU2355375C1 (en) | Wound repair process in diabetic foot neuropathy | |
| RU2082457C1 (en) | Method for correcting posthemorrhagic syndrome in patients suffering from ulcerous gastroduodenal hemorrhage | |
| RU2362591C1 (en) | Way of treatment of burn disease at children with serious thermal trauma | |
| RU2699967C1 (en) | Method for complex treatment of enteral insufficiency in children with severe thermal trauma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20040416 |